3results about How to "Extend cycle time" patented technology

This invention provides the application of the LHPP gene in liver cancer immunotherapy and liver cancer immunotherapy drugs. Reagents that promote LHPP gene expression can be used to prepare liver cancer immunotherapy drugs. This invention also provides an mRNA nanomedicine, which is prepared by the following method: [The invention then describes a process involving Meo-PEG-Dlink]. m A PLGA solution, an aqueous solution of LHPP gene mRNA, and a cationic liposome solution were mixed and added dropwise to water under stirring to obtain a nanosolution. The nanosolution was then transferred to an ultrafiltration membrane and centrifuged. This invention is the first to discover that LHPP can participate in the immunotherapy of liver cancer and is associated with the survival prognosis of liver cancer. LHPP enhances STAT1 nuclear translocation by affecting the expression of autophagy-regulated IFNβ, thereby promoting the expression of T cell-related chemokines secreted by liver cancer cells, and ultimately promoting CD8+ expression. + T cell infiltration. Therefore, the LHPP gene can serve as a novel target for immunotherapy of liver cancer. The mRNA nanomedicine described has advantages such as long circulation time in the blood, high accumulation in tumors, rapid mRNA release, and low cost.

The present invention relates to processes for the preparation of Tyk2 inhibitors. In particular, the present invention relates to improved processes for the synthesis of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide, Compound I, which is currently in clinical trials for the treatment of autoimmune and autoinflammatory diseases such as psoriasis.

This invention discloses a bioactive nanomicelle based on idebenone. By designing idebenone molecules with hydrophobic ends and functionalized hydrophilic polyethylene glycol, it exhibits excellent responsiveness, antioxidant properties, and cellular safety, making it suitable as a carrier for delivering drugs, genes, or other bioactive molecules for therapeutic and diagnostic applications. This invention also discloses a method for preparing this idebenone-based bioactive nanomicelle. The method for synthesizing the amphiphilic polymer of IDBP is simple, with mild reaction conditions, easy synthesis, convenient post-processing, high yield, and easy industrial production. The prepared amphiphilic polymer exhibits spontaneous assembly behavior in aqueous solution, forming a stable nanomicelle structure. This demonstrates the great potential of idebenone-based bioactive nanomicelles in drug delivery, potentially improving drug stability, bioavailability, and targeting.